engineered CAR NK cells that target NKG2D for the treatment of multiple myeloma (MM), compare to the group of memory-like CAR T-cells transduced with NKG2D, the mice that received the CAR NK cells demonstrated prolonged disease-free survival and exhibited a significant reduction in plasma cells in the bone marrow (78). This evidence concerns the gene KLRK1 and plasma cell myeloma.